| 1 |
34568053 | ALK Rearrangement-Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report. | 2021 |
1 |
| 2 |
30352902 | Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. | 2019 Feb 15 |
1 |
| 3 |
30412912 | Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib. | 2019 Feb |
4 |
| 4 |
30072474 | Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. | 2018 Dec 1 |
4 |
| 5 |
28007627 | Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). | 2017 Apr |
1 |
| 6 |
28601386 | Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. | 2017 Nov |
2 |
| 7 |
26381283 | EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect. | 2016 Jan |
1 |
| 8 |
26898615 | K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature. | 2016 Mar |
2 |
| 9 |
27040858 | EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient. | 2016 May |
1 |
| 10 |
25691052 | Activation of RAS family members confers resistance to ROS1 targeting drugs. | 2015 Mar 10 |
1 |
| 11 |
26517679 | Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells. | 2015 Nov 24 |
1 |
| 12 |
25232318 | Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary. | 2014 May |
1 |